MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories (NASDAQ:MLAB) has announced its Board of Directors' declaration of a regular quarterly dividend of $0.16 per share of common stock. The dividend will be paid on March 17, 2025, to shareholders of record as of the close of business on February 28, 2025.
Mesa Labs operates as a global leader in designing and manufacturing life science tools and critical quality control solutions, primarily serving regulated applications in the pharmaceutical, healthcare, and medical device industries. Their products and services aim to ensure product integrity, enhance patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB) ha annunciato la dichiarazione del suo Consiglio di Amministrazione riguardo a un dividendo trimestrale regolare di 0,16 $ per azione di azioni ordinarie. Il dividendo sarà pagato il 17 marzo 2025 agli azionisti registrati alla chiusura dei mercati del 28 febbraio 2025.
Mesa Labs opera come leader globale nella progettazione e produzione di strumenti per le scienze della vita e soluzioni critiche per il controllo di qualità, servendo principalmente applicazioni regolamentate nei settori farmaceutico, sanitario e dei dispositivi medici. I loro prodotti e servizi mirano a garantire l'integrità del prodotto, migliorare la sicurezza dei pazienti e dei lavoratori e migliorare la qualità della vita in tutto il mondo.
Mesa Laboratories (NASDAQ:MLAB) ha anunciado la declaración de su Junta Directiva de un dividendo trimestral regular de 0,16 $ por acción de acciones ordinarias. El dividendo se pagará el 17 de marzo de 2025 a los accionistas registrados al cierre de la jornada del 28 de febrero de 2025.
Mesa Labs opera como un líder global en el diseño y fabricación de herramientas de ciencias de la vida y soluciones críticas de control de calidad, sirviendo principalmente aplicaciones reguladas en las industrias farmacéutica, de salud y de dispositivos médicos. Sus productos y servicios tienen como objetivo garantizar la integridad del producto, mejorar la seguridad de los pacientes y trabajadores, y mejorar la calidad de vida en todo el mundo.
메사 연구소 (NASDAQ:MLAB)는 이사회가 보통주 1주당 $0.16의 정기 분기 배당금을 선언했다고 발표했습니다. 배당금은 2025년 3월 17일에 지급되며, 2025년 2월 28일 마감 기준으로 주주에게 지급됩니다.
메사 연구소는 생명 과학 도구 및 품질 관리 솔루션 설계와 제조 분야의 글로벌 리더로 활동하며, 주로 제약, 의료 및 의료기기 산업의 규제 애플리케이션을 제공합니다. 이들의 제품과 서비스는 제품의 무결성을 보장하고, 환자와 근로자의 안전을 향상시키며, 전 세계의 삶의 질을 개선하는 것을 목표로 합니다.
Mesa Laboratories (NASDAQ:MLAB) a annoncé la déclaration par son Conseil d'Administration d'un dividende trimestriel régulier de 0,16 $ par action d'actions ordinaires. Le dividende sera versé le 17 mars 2025 aux actionnaires inscrits à la clôture des échanges le 28 février 2025.
Mesa Labs opère en tant que leader mondial dans la conception et la fabrication d'outils pour les sciences de la vie et de solutions critiques de contrôle de la qualité, servant principalement des applications réglementées dans les secteurs pharmaceutique, de la santé et des dispositifs médicaux. Leurs produits et services visent à garantir l'intégrité du produit, à améliorer la sécurité des patients et des travailleurs, et à améliorer la qualité de vie dans le monde entier.
Mesa Laboratories (NASDAQ:MLAB) hat die Erklärung des Vorstands zu einer regulären vierteljährlichen Dividende von 0,16 $ pro Aktie auf Stammaktien bekannt gegeben. Die Dividende wird am 17. März 2025 an die zum 28. Februar 2025 geschlossenen Aktionäre ausgezahlt.
Mesa Labs ist ein weltweit führendes Unternehmen in der Gestaltung und Herstellung von Werkzeugen für die Lebenswissenschaften und kritischen Lösungen für die Qualitätskontrolle, das hauptsächlich regulierte Anwendungen in der Pharma-, Gesundheits- und Medizingeräteindustrie bedient. Ihre Produkte und Dienstleistungen zielen darauf ab, die Integrität der Produkte zu gewährleisten, die Sicherheit von Patienten und Mitarbeitern zu verbessern und die Lebensqualität weltweit zu steigern.
- Maintains consistent quarterly dividend payment of $0.16 per share
- Demonstrates financial stability and commitment to shareholder returns
- None.
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2024, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
For more information about the Company, please visit its website at www.mesalabs.com
FAQ
What is Mesa Labs (MLAB) quarterly dividend amount for Q1 2025?
When is the payment date for Mesa Labs' Q1 2025 dividend?
What is the record date for Mesa Labs' latest dividend?
What industries does Mesa Labs (MLAB) serve with its products?
